IOL Chemicals & Pharmaceuticals Ltd Q2 FY2026 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/vblsxlxulq1o8tqca432bm6y.pdf

Key Takeaways


Paracetamol Scale-Up

Mahajan: "As regard to -- as you've rightly said that the demand of paracetamol is not increasing but as for IOL is concerned, our demand is increasing to some extent as earlier capacity of paracetamol was 3,600 metric ton. But in March '25, we've started -- enhanced capacity of 11,800 and we've already reached around 55% to 60% capacity utilization for -- you can say in the first 6 months, we have already crossed last year capacity."

Margin Bridge: The Q2 Miss

Khanna: "Actually, regarding EBITDA margin, we expect and declared the target in the previous con calls about 13% to 14% but we are not able to achieve the target in the quarter due to unexpected rise in fuel costs, due to heavy rains and floods."

Non-Ibuprofen Pharma & Pipeline

Rana: "As of now, we are not doing this because of the price war in the market because whatever the price is there in the market, that is not even the cost of production."

Revenue Growth & Mix

DriverTrendCommentary
Non-Ibuprofen pharma▲ Volume growthParacetamol, Clopidogrel, Pantoprazole leading; export optimism for Q3/Q4.
Ibuprofen▬ StableSmall U.S. exports; no tariff impact as generics are exempt.
Chemicals▬ FlattishVolume gains offset by pricing pressure; margin improved on procurement gains.
Domestic share▲ RisingIncreased to 76% of H1 revenue (from 74% in Q1) as higher paracetamol capacity fed domestic supply; export value roughly flat.
Singh: "I think a little bit we could not reach to that level within this H1. But for H2, we are hopeful that we will be achieving 10%, 12% from now, maybe a little bit short as compared to the whole year, but we are -- we will be reaching very close to that."

Regulatory & Market Access


Costs, Capex & Balance Sheet


Guidance & Commitments

CommitmentSpecificsTimeline
Paracetamol capacity utilizationReach 65% (from current 55%)By March 2025 end
H2 revenue growthAchieve 10-12% growthH2 FY26
Power cost normalizationReduce by INR5-6 crores toward normal levelsCurrent quarter (Q3 FY26)
Land regulatory approvalsAll pending approvals receivedWithin 2 quarters
FY27 revenue targetINR2,600-2,700 croresFY27
FY27 EBITDA margin target13% to 15%FY27
Annual revenue growth ambition10% to 15% every yearOngoing
Annual EBITDA margin expansion1% to 2% increase every yearOngoing
Pharma mix target50% Ibuprofen, 50% other pharma products"Coming years"
Non-Ibuprofen export growthDefinite increaseQ3 and Q4 FY26

Key Metrics

MetricQ2 FY26
Revenue from operations₹567.5 cr, 7.9% YoY growth
EBITDA margin11.8% in H1 FY26, up from 10.2% in H1 FY25; Q2 impacted ~1% by higher fuel costs
PAT growth33% YoY growth, driven by volume, product mix, and shift to regulated customers
Power and fuel cost impact₹7–8 cr incremental cost in Q2 due to floods, expected to normalize by ₹5–6 cr in Q3
Employee variable pay impact~₹6 cr one-time impact in Q2, not recurring in Q3/Q4
Pharma segment revenue mixIbuprofen 62%, other APIs 38% of pharma revenue
Overall revenue mixPharma 59%, Chemicals 41%
Paracetamol capacity utilization55% in Q2 (new 11,800 MT plant), target 65% by March 2026
Ethyl acetate capacity utilization~100%
Acetic anhydride captive use~60% of production
Capex incurred in H1 FY26~₹60 cr of the ₹150–200 cr full-year plan
Maintenance vs growth capex split40% maintenance, 60% growth
FY27 revenue target₹2,600–2,700 cr
FY27 EBITDA margin target13–15%